MannKind has a market cap of $1.81 billion and is part of the health care sector and drugs industry. Shares are up 169.7% year to date as of the close of trading on Thursday.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States.

TheStreet Ratings rates MannKind as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and weak operating cash flow.

http://www.thestreet.com/story/11933674/1/mannkind-stock-falls-on-unusually-high-volume-mnkd.html?puc=yahoo&cm_ven=YAHOO